Akebia crashes on vadadustat flop in larger anemia indication. Will AZ, FibroGen own the market?
What was previously expected to be a three-way battle in the novel HIF-PHI renal anemia drug class now has one man down. Akebia Therapeutics has posted a surprise trial flop, which one analyst said could hand the rival FibroGen-AstraZeneca team an early monopoly of the market. On Thursday, Akebia said its Otsuka-partnered vadadustat was linked to… Read More »